EBOS Group Limited (ASX:EBO): FY26 Earnings and FY27 Operating Update

Aditi Sarkar

22 October 2026 04:20 PM AEDT

EBOS Group Limited (ASX:EBO): FY26 Earnings and FY27 Operating Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EBOS Group (ASX:EBO) reported FY26 revenue of AUD 13.49 billion, up 9.9%.
Underlying FY26 EBITDA reached AUD 614 million; underlying net profit declined 3.1%.
The group completed its distribution-centre renewal programme, with eight facilities operational.
At its October annual meeting, EBOS reaffirmed FY27 guidance despite fuel and currency pressures.

EBOS Group Limited (ASX:EBO) distributes healthcare, pharmaceutical and medical products and supplies animal care products across Australasia and parts of Asia. At the time of writing on 22 October 2026, EBOS shares were quoted at AUD 17.06, down 0.12% in the trading figures under review. The company’s latest update at its October annual meeting addressed first-quarter FY27 operations, expenditure and guidance following publication of its FY26 results in August.

Company Business

EBOS Group (ASX:EBO) reports through Healthcare and Animal Care segments, with four operating divisions. Symbion and Healthcare Distribution supplies pharmacies, hospitals and healthcare partners; Retail Pharmacy Brands provides branding, services and retail support to independent pharmacies. Medical Technology distributes specialist equipment, biologics and related products to healthcare providers. Animal Care manufactures and markets pet food and distributes veterinary products. Operations span Australia, New Zealand, Southeast Asia and Hong Kong, with different demand patterns and operating costs across these markets.

The healthcare businesses are exposed to medicine distribution volumes, customer contracts, pharmacy services and demand for specialist medical products. Animal Care includes pet-food brands and veterinary wholesale channels. These activities require distribution capacity, inventory management and supplier relationships, making network productivity and working-capital control important operating measures.

Recent Development

At the 21 October 2026 annual meeting, EBOS Group (ASX:EBO) said growth had continued in the first quarter of FY27 and reaffirmed its existing FY27 guidance, while noting continuing foreign-exchange and fuel-cost pressures. Management indicated that earnings growth was expected to be weighted toward the second half of the financial year. This is company guidance rather than a reported outcome.

The group said its eight renewed distribution facilities were operational by 30 June 2026. It reported approximately AUD 145 million of FY26 capital expenditure and indicated FY27 expenditure remained on track for around AUD 100 million. At Kemps Creek, warehouse productivity was approximately 20% above the previous Greystanes site; management outlined a further improvement target as automation and volumes develop.

Retail Pharmacy Brands supported approximately 790 stores following around ten net additions during the quarter. The group also reported an extension to its New Zealand Chemist Warehouse wholesaling agreement, with a progressive rundown through FY28, and highlighted expansion of medical technology supplier partnerships and animal care sales. These developments provide operating context beyond the annual earnings figures.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, EBOS Group (ASX:EBO) reported revenue of AUD 13.487 billion, an increase of 9.9% from AUD 12.267 billion. Underlying EBITDA increased 5.0% to AUD 614 million from AUD 585 million, while statutory EBITDA was AUD 599 million, up 7.8%. The difference reflects adjustments made in the group’s underlying reporting measures.

Underlying net profit after tax declined 3.1% to AUD 250 million from AUD 258 million, which the group attributed principally to depreciation, amortisation and financing costs following its distribution investment cycle. Statutory net profit increased 4.7% to AUD 225 million. The leverage ratio was 2.1 times, inside the company’s stated 1.7–2.3 times range; return on capital employed was 12.8%.

Healthcare contributed AUD 12.58 billion of FY26 revenue and AUD 516 million of underlying EBITDA. Its revenue increased 8.5%, while underlying EBITDA rose 3.2%. The segment experienced higher freight and foreign-exchange costs alongside demand for higher-value medicines. EBOS reported a final dividend of NZD 0.615 per share and an FY26 total dividend of NZD 1.185 per share. The distinction between Australian-dollar earnings and New Zealand-dollar dividends is material.

Risks to Consider

For EBOS Group (ASX:EBO), principal disclosed pressures include fuel and energy expenditure, currency movements, changes in customer arrangements, competition in pharmacy distribution and execution of warehouse productivity initiatives. Higher financing and depreciation costs affected underlying profit in FY26. The transition of a New Zealand wholesale contract through FY28 and the integration of acquisitions may also influence segment performance.

What to Watch Next

EBOS Group (ASX:EBO) has indicated FY27 capital expenditure of approximately AUD 100 million and expects the renewed logistics network to improve utilisation and productivity. Relevant reporting points include the development of first-quarter operating trends into the second half, progress at Kemps Creek, cash conversion, leverage and delivery against the reaffirmed FY27 guidance. Pharmacy network additions, medical technology acquisitions and animal care demand remain operating measures to follow.

Key Insights

EBOS enters FY27 with a completed major distribution investment programme, FY26 revenue growth and a decline in underlying net profit. Its October update reported continued first-quarter growth and reaffirmed guidance, while identifying ongoing cost and currency pressures. The relationship between capital expenditure, operating efficiency, cash flow and earnings will be central to assessing subsequent financial disclosures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.